CHENNAI: The first phase of Schneider Electric’s five lakh sq ft manufacturing facility at Horizon Industrial Park in Hosur will be ready by January 2026.

Biogen Launches Phase 3 Pediatric Trial Of Omaveloxolone For Friedreich Ataxia. Published on June 23, 2025 at 1:36 am by Fatima Gulzar in News ...

TOKYO & BASKING RIDGE, N.J., June 09, 2025--DESTINY-Endometrial01 Ph. 3 Trial of ENHERTU Initiated as 1L Therapy in Patients w/ HER2 Expressing Primary Advanced or Recurrent Endometrial Cancer ...

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).. If you have the appropriate software ...

In its first global phase 3 readout, Akeso and Summit Therapeutics’ closely watched PD-1xVEGF bispecific antibody ivonescimab reduced the risk of progression or death by 48% in patients with ...

ISLAMABAD: The government’s second-phase auction for three dysfunctional or closed thermal power plants received a lukewarm response, with only one party submitting a bid — for the Jamshoro ...

"These Phase 3 topline results are highly encouraging and represent the potential for a much-needed innovation in the treatment of OSA," said Patrick Strollo, Jr., MD, study chair of the SynAIRgy ...

In every patch, HoYoverse introduces several new events, and the upcoming Honkai Star Rail 3.3 update isn't an exception.

In summary, all of the new and returning 5-Star characters you can Warp on during 3.3 are: Hyacine (A Rainbow onto Twilight Banner - Phase 1): New 5-Star Wind character of The Remembrance path.

Mumbai: The much-anticipated Phase 2 of Mumbai Metro Line 3 is nearing the finish line, with the 9.8-kilometre underground stretch from Bandra Kurla Complex (BKC) to Worli (Acharya Atre Chowk ...

ORIGIN 3 follows the positive long-term results from the ORIGIN Phase 2b trial that demonstrated sustained and substantial reductions in Gd-IgA1, hematuria and proteinuria, and showed stabilized ...

Investing.com -- Shares of Corcept Therapeutics (NASDAQ: CORT) Incorporated (NASDAQ: CORT) surged 90% following the announcement of positive results from its pivotal Phase 3 ROSELLA trial.